Journal ArticleDOI
Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol
Paul G. Richardson,Angela R. Smith,Sally Arai,Stephan A. Grupp,Nancy A. Kernan,Roberta H. Adams,Paul L. Martin,Sunil Abhyankar,Alfred P. Gillio,Michael Grimley,Leslie Lehmann,Paul R. Haut,Amanda Termuhlen,Joseph H. Antin,Thomas R. Spitzer,David Avigan,Joseph M. Massaro,Alison L. Hannah,Massimo Iacobelli,Robert J. Soiffer +19 more
Reads0
Chats0
TLDR
DF in the treatment of severe VOD/MOF post-SCT demonstrated a complete response (CR) in 36–46% of patients, and key exclusion criteria included clinically significant bleeding or need for >1 pressor to maintain BP.About:
This article is published in Blood.The article was published on 2010-11-19. It has received 7 citations till now.read more
Citations
More filters
Book ChapterDOI
Animal models of hemophilia.
Denise E. Sabatino,Timothy C. Nichols,Elizabeth P. Merricks,Dwight A. Bellinger,Roland W. Herzog,Paul E. Monahan +5 more
TL;DR: While murine models are excellent for studies of large groups of animals using genetically defined strains, canine models are important for testing scale-up and for long-term follow-up as well as for studies that require larger blood volumes.
Journal ArticleDOI
Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation
Selim Corbacioglu,Nancy A. Kernan,Leslie Lehmann,Joel A. Brochstein,Carolyn Revta,Stephan A. Grupp,Paul L. Martin,Paul G. Richardson +7 more
TL;DR: The most promising agent to date is defibrotide, a novel polydeoxyribonucleotide with fibrinolytic properties but no major bleeding risk as mentioned in this paper.
Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell
Selim Corbacioglu,Nancy A. Kernan,Leslie Lehmann,Joel A. Brochstein,Carolyn Revta,Stephan A. Grupp,Paul L. Martin,Paul G. Richardson +7 more
TL;DR: The most promising agent to date is defibrotide, a novel polydeoxyribonucleotide with fibrinolytic properties but no major bleeding risk as mentioned in this paper.
Journal ArticleDOI
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease
Paul G. Richardson,Vincent T. Ho,Sergio Giralt,Sally Arai,Shin Mineishi,Corey Cutler,Joseph H. Antin,Nicole Stavitzski,Dietger Niederwieser,Ernst Holler,Enric Carreras,Robert J. Soiffer +11 more
TL;DR: Defibrotide, a polydisperse oligonucleotide, has been shown in phase II and III trials to improve complete response and survival in patients undergoing SCT with severe VOD.
Journal ArticleDOI
How can we reduce hepatic veno-occlusive disease–related deaths after allogeneic stem cell transplantation?
TL;DR: With appropriate management steps, the incidence of VOD and related deaths can be further decreased and the institution pursues aggressive preventative measures for VOD, including appropriate conditioning regimen selection, avoiding hepatotoxic drugs, early prophylactic use of ursodiol, and aggressive fluid management.
Related Papers (5)
Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).
Paul G. Richardson,Gideon Steinbach,Nancy A. Kernan,Eva C. Guinan,Allen R. Chen,Paul L. Martin,Amrita Krishnan,Sally Arai,Joel A. Brochstein,Stephan A. Grupp,Shin Mineishi,Amanda Termuhlen,Marcie Tomblyn,Joseph H. Antin,Carolyn Revta,Robin Hume,Joseph M. Massaro,Alison L. Hannah,Massimo Iacobelli,Robert J. Soiffer +19 more
Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol
Paul G. Richardson,Angela R. Smith,Stephan A. Grupp,Nancy A. Kernan,Sally Arai,Paul R. Haut,Brandon M. Triplett,Alfred P. Gillio,Heather J. Symons,Roberta H. Adams,Biljana Horn,Kenneth G. Lucas,Paul L. Martin,Shin Mineishi,Edward D. Ball,Michael Boyer,John Fort,Ivan I. Kirov,Leslie Lehmann,Catherine Madigan,Michelle E. Maglio,Joseph M. Massaro,Ralph B. D'Agostino,Alison L. Hannah,Elena Tudone,Robin Hume,Massimo Iacobelli,Robert J. Soiffer +27 more
Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol
Paul G. Richardson,Angela R. Smith,Nancy A. Kernan,Stephan A. Grupp,Sally Arai,Brandon M. Triplett,Paul R. Haut,Kawah Chan,Heather J. Symons,Biljana Horn,Alfred P. Gillio,Michael Boyer,Amrita Krishnan,Leslie Lehmann,Paul L. Martin,Shin Mineishi,Tsiporah B. Shore,Tiffany Simms-Waldrip,Joseph H. Antin,Alison L. Hannah,Robin Hume,Elena Tudone,Carin Heringa,Robert J. Soiffer +23 more
Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial.
Paul G. Richardson,Robert J. Soiffer,Joseph H. Antin,Zhezhen Jin,Joanne Kurtzberg,Paul L. Martin,Gideon Steinbach,K. F. Murray,Georgia B. Vogelsang,Allen R. Chen,Aparna Krishnan,Nancy A. Kernan,David Avigan,Thomas R. Spitzer,Diane Warren,Carolyn Revta,L. J. Wei,Massimo Iacobelli,George B. McDonald,Eva C. Guinan +19 more